Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Department of Gynecology, The Forth Hospital of Hebei Medical University, Shijiazhuang, China.
J Obstet Gynaecol Res. 2023 Jun;49(6):1592-1610. doi: 10.1111/jog.15633. Epub 2023 Mar 14.
We aimed to compare the 5-year oncological outcomes of laparoscopic/abdominal radical hysterectomy (LRH/ARH) in patients with cervical adenosquamous carcinoma at stage IA2 to IIA2 based on the 2009 or 2018 International Federation of Gynecology and Obstetrics (FIGO) staging criteria.
Based on the clinical diagnosis and treatment of cervical cancer in China (Four C) database, Cox risk regression models were applied to analyze tumor prognosis treated with ARH/LRH in FIGO 2009 and 2018 IA2-IIA2 patients and stratified findings according to tumor diameter (≤4 and >4 cm subgroups). And to avoid bias, propensity score matching (PSM) was also used for the cohort study.
Based on FIGO 2009 staging criteria (n = 474), there was no significant difference between the ARH and LRH groups in 5-year disease-free survival (DFS) or overall survival (OS). Lymph node metastasis was a risk factor for 5-year DFS in this stage. After PSM, lymphovascular space invasion (LVSI) was an independent risk factor for 5-year OS in the tumors ≤4 cm subgroup. Based on FIGO2018 staging criteria (n = 322), cervical interstitial infiltration depth was an independent risk factor for 5-year OS in the total population and the tumor diameter ≤4 cm subgroup.
Laparoscopic surgery was not a risk factor affecting the oncologic prognosis of adenosquamous carcinoma of the cervix based on either FIGO 2009 or 2018 staging of stage IA2-IIA2. In addition, LRH may be considered for patients with early-stage cervical adenosquamous carcinoma.
我们旨在比较基于 2009 年或 2018 年国际妇产科联合会(FIGO)分期标准,IA2 期至 IIA2 期宫颈腺鳞癌患者腹腔镜/经腹广泛子宫切除术(LRH/ARH)的 5 年肿瘤学结果。
基于中国宫颈癌临床诊断与治疗(四C)数据库,应用 Cox 风险回归模型分析 ARH/LRH 治疗 FIGO 2009 年和 2018 年 IA2-IIA2 期患者肿瘤预后,并根据肿瘤直径(≤4cm 和>4cm 亚组)进行分层分析。为了避免偏倚,还对队列研究进行了倾向评分匹配(PSM)。
根据 FIGO 2009 分期标准(n=474),在 5 年无病生存率(DFS)或总生存率(OS)方面,ARH 组和 LRH 组之间无显著差异。淋巴结转移是该期 5 年 DFS 的危险因素。PSM 后,在肿瘤直径≤4cm 的亚组中,血管淋巴管间隙浸润(LVSI)是 5 年 OS 的独立危险因素。根据 FIGO2018 分期标准(n=322),在总人群和肿瘤直径≤4cm 亚组中,宫颈间质浸润深度是 5 年 OS 的独立危险因素。
腹腔镜手术不是影响基于 FIGO 2009 或 2018 分期的 IA2-IIA2 期宫颈腺鳞癌肿瘤学预后的危险因素。此外,LRH 可考虑用于早期宫颈腺鳞癌患者。